The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment - Concepedia

Concepedia

Publication | Open Access

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

DOI Full Paper Access

80

Citations

20

References

2020

Year

Gema Ariceta, Bradley P. Dixon, Seong Heon Kim, Gaurav Kapur, Teri Jo Mauch, Stephan Ortiz, Marc Vallée, Andrew Denker, Hee Gyung Kang, Larry A. Greenbaum,

Kidney International

References

	Year	Citations

Page 1